Investor Relations

Overview

NuGenerex Immuno-Oncology, Inc. is a clinical stage biotechnology company focused on harnessing the power of the innate immune system to treat cancer and infectious disease with a pipeline of immunotherapy indications based on our proprietary, patented platform technology, Ii-Key.

The Company’s lead immunotherapy product candidate is AE37, an Ii-Key-HER2 peptide vaccine for breast, prostate, and bladder cancer which incorporates our li-peptide linker to a designated antigen that activates the immune system targeting specific cancer cells. Ex-Vivo human studies are currently underway for our COVID Ii-Key Complete Vaccine and clinical trials are expected to begin in early 2021.

Latest News

Investor Presentation